Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (7023)	3/15/2005 3:30:59 PM
From: D. K. G.	Read Replies (2) \| Respond to of 23958

Nice call on ccur. Added some CRNS last week 11.96. my bad on earning release, look for end of month not middle as it is the PY end. GCFC shareholders have approved 1-325 RS. Still some risk the board will not do it, if it cost more than 2 million, final in 2 wks. Worth the risk IMO. INKP, profitable company with good growth making a bottom... 139.142.147.218 InKine Pharmaceutical Company, Inc. is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to diagnose and treat gastrointestinal disorders. The Company markets and sells two pharmaceutical products, Visicol and IB-Stat. Visicol (brand of sodium phosphate tablets) is a United States Food and Drug Administration-approved tablet purgative preparation that is indicated for bowel cleansing prior to colonoscopy. IB-Stat is an antispasmodic product marketed to gastroenterologists and others for use as an acute care product available for absorption more rapidly than solid dose formulations that is used for a variety of indications. In addition to its marketed products, the Company has identified two product candidates, a microcrystalline cellulose-free new generation purgative tablet, INKP-102, and Colirest, which is being evaluated for treatment of Crohn's disease and ulcerative colitis. For the fiscal year ended 12/31/04, revenues rose 53% to $22.1 million. Net income totaled $3.1 million, vs. a loss of $1.5 million. Revenues reflect increased market awareness and acceptance of Visicol. Net income also reflects improved margins, fewer interest costs, and the absence of non-cash accretion and premium provisions.